- Trial Phase
- Phase 2
- Time to Market
- Uncertain — at least 3-5 years if a Phase 3 trial is initiated and successful. No Phase 3 trial has been started, and the company may not have the cash to fund one without a partnership or dilutive financing.
- Why 4/10
- No hard dated binary catalyst is scheduled in the next ~12 months — the Phase 2 mPDAC data is already published, the oral tablet Phase 1/2 study was expected to initiate 2H 2026 but has no specific start date, and the BEACON2 neuroblastoma trial is early-stage with no fixed readout. The next major event is likely a dilutive financing (S-1/A already filed) rather than a clinical binary, so the impact score defaults to 4.
The looming going-concern risk and dilutive S-1 offering overhang are the dominant near-term forces — the clinical data is promising but irrelevant if the company cannot finance operations. Watch for the outcome of the S-1/A offering filing (pricing and terms), any partnership/licensing deal that could provide non-dilutive capital, and the initiation of the oral tablet Phase 1/2 study before considering a position. The stock is 93% off its 52-week high and the massive analyst upside targets reflect a binary, high-risk setup rather than a smooth path to value creation.
Price Chart
Executive Summary
Actuate Therapeutics (NASDAQ: ACTU) is a clinical-stage, single-asset biotech developing elraglusib, a GSK-3β inhibitor for difficult-to-treat cancers. The drug showed promising Phase 2 data in metastatic pancreatic cancer — a 2.9-month median overall survival improvement and a doubling of the 1-year survival rate — published in Nature Medicine. It also holds FDA Rare Pediatric Disease designation for neuroblastoma and is being studied in an oral tablet formulation. Despite the encouraging clinical signal, the company faces an existential going-concern risk with only $4.4M in cash, has filed massively dilutive S-1/A offerings, and received a Nasdaq non-compliance notice. The stock is down ~93% over 12 months to ~$0.48, with heavy institutional exiting and persistently elevated short volume. While analyst price targets imply massive upside (mean ~$11.68), this reflects binary lottery-ticket dynamics rather than a clear path to commercialization.
How It Works
Elraglusib is a small-molecule drug that inhibits GSK-3β (Glycogen Synthase Kinase 3 beta), an enzyme that cancer cells use to survive, proliferate, and resist chemotherapy. By blocking GSK-3β, elraglusib aims to make cancer cells more vulnerable to chemotherapy and boost the immune system's ability to attack tumors. It is being studied mainly in pancreatic cancer and neuroblastoma (a rare childhood cancer), given either intravenously or as an oral tablet.
Trial Status
Completed a randomized Phase 2 trial (n=233) in first-line metastatic pancreatic cancer with positive survival data published in Nature Medicine. FDA has cleared an IND for a Phase 1/2 oral tablet study in advanced solid tumors (initiation planned 2H 2026). Elraglusib was also selected for the BEACON2 platform Phase 1/2 trial in relapsed/refractory neuroblastoma, sponsored by Cancer Research UK. A prior Phase 1/2 neuroblastoma study (NCT04239092) showed a complete bone marrow response in one heavily pretreated patient.
The Two-Sided Case
Upcoming Catalysts
- Pricing and completion of the dilutive S-1/A public offering (any day/week — filings already submitted)
- Initiation of the Phase 1/2 oral tablet study in advanced solid tumors (expected 2H 2026)
- BEACON2 neuroblastoma platform trial data updates (no fixed timeline)
- Potential partnership or licensing deal for elraglusib to alleviate cash crunch
- Nasdaq compliance deadline of January 11, 2027 for MVLS requirement
- RAS combination preclinical data (initially expected Q2 2026 per March press release)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
ACTUATE THERAPEUTICS, INC. S-1/A ACTU ·Originating report